- Home
- RAPT vs NKTX Comparison
RAPT vs NKTX Comparison
Compare RAPT & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- NKTX
- Stock Information
- Founded
- RAPT 2015
- NKTX 2015
- Country
- RAPT United States
- NKTX United States
- Employees
- RAPT N/A
- NKTX N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- RAPT Health Care
- NKTX Health Care
- Exchange
- RAPT Nasdaq
- NKTX Nasdaq
- Market Cap
- RAPT 122.9M
- NKTX 123.5M
- IPO Year
- RAPT 2019
- NKTX 2020
- Fundamental
- Price
- RAPT $11.74
- NKTX $2.33
- Analyst Decision
- RAPT Buy
- NKTX Strong Buy
- Analyst Count
- RAPT 5
- NKTX 5
- Target Price
- RAPT $33.60
- NKTX $13.50
- AVG Volume (30 Days)
- RAPT 105.9K
- NKTX 553.5K
- Earning Date
- RAPT 08-07-2025
- NKTX 08-12-2025
- Dividend Yield
- RAPT N/A
- NKTX N/A
- EPS Growth
- RAPT N/A
- NKTX N/A
- EPS
- RAPT N/A
- NKTX N/A
- Revenue
- RAPT N/A
- NKTX N/A
- Revenue This Year
- RAPT N/A
- NKTX N/A
- Revenue Next Year
- RAPT N/A
- NKTX N/A
- P/E Ratio
- RAPT N/A
- NKTX N/A
- Revenue Growth
- RAPT N/A
- NKTX N/A
- 52 Week Low
- RAPT $5.67
- NKTX $1.31
- 52 Week High
- RAPT $26.56
- NKTX $6.63
- Technical
- Relative Strength Index (RSI)
- RAPT 58.44
- NKTX 65.48
- Support Level
- RAPT $10.20
- NKTX $1.96
- Resistance Level
- RAPT $13.50
- NKTX $2.26
- Average True Range (ATR)
- RAPT 1.01
- NKTX 0.14
- MACD
- RAPT -0.05
- NKTX 0.01
- Stochastic Oscillator
- RAPT 77.46
- NKTX 77.32
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.